|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.7200 - 1.7200|
|52 Week Range||0.4200 - 1.8800|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||191.11|
|Earnings Date||Apr 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire, and successful treatment of the first patients. The SavvyWire, developed initially for transcatheter aortic valve replacement ("TAVR"), is the first guidewire intended to both deliver a valvular prosthesis while allowing co
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021, at 9:30 AM ET.